Revolutionizing the pharmaceutical industry, MIT chemical engineers have developed an AI model that could significantly reduce the costs of protein drug development. This groundbreaking study leverages the power of artificial intelligence to optimize the manufacturing of vaccines, biopharmaceuticals, and other essential compounds using industrial yeasts like Komagataella phaffii. By harnessing a large language model (LLM), the researchers analyzed the genetic code of K. phaffii, focusing on the codons used to encode specific amino acids. The model learned the patterns of codon usage for this yeast and predicted the most efficient codons for producing various proteins, including human growth hormone and a cancer-treating monoclonal antibody. This innovative approach not only boosts production efficiency but also reduces the time and cost associated with developing and manufacturing these drugs. The study, led by J. Christopher Love, demonstrates the potential of AI in streamlining the biopharmaceutical industry, offering a more reliable and predictable process for codon optimization. With further research, this technology could revolutionize the way we produce life-saving medications.
